525 related articles for article (PubMed ID: 28438619)
21. Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.
Matsuki E; Bohn OL; El Jamal S; Pichardo JD; Zelenetz AD; Younes A; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):572-580. PubMed ID: 30106758
[TBL] [Abstract][Full Text] [Related]
22. Immunocyte density in parathyroid carcinoma is correlated with disease relapse.
Hu Y; Cui M; Bi Y; Zhang X; Wang M; Hua S; Liao Q; Zhao Y
J Endocrinol Invest; 2020 Oct; 43(10):1453-1461. PubMed ID: 32219691
[TBL] [Abstract][Full Text] [Related]
23. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.
Marchesi F; Cirillo M; Bianchi A; Gately M; Olimpieri OM; Cerchiara E; Renzi D; Micera A; Balzamino BO; Bonini S; Onetti Muda A; Avvisati G
Hematol Oncol; 2015 Jun; 33(2):110-2. PubMed ID: 24711044
[No Abstract] [Full Text] [Related]
24. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
Alzahrani M; El-Galaly TC; Hutchings M; Hansen JW; Loft A; Johnsen HE; Iyer V; Wilson D; Sehn LH; Savage KJ; Connors JM; Gascoyne RD; Johansen P; Clasen-Linde E; Brown P; Villa D
Ann Oncol; 2016 Jun; 27(6):1095-1099. PubMed ID: 27002106
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Impact of CD163+ Macrophages in Tumor Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct Cancer.
Miura T; Yoshizawa T; Hirai H; Seino H; Morohashi S; Wu Y; Wakiya T; Kimura N; Kudo D; Ishido K; Toyoki Y; Kijima H; Hakamada K
Anticancer Res; 2017 Jan; 37(1):183-190. PubMed ID: 28011489
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
28. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
[TBL] [Abstract][Full Text] [Related]
29. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
Yao Z; Deng L; Xu-Monette ZY; Manyam GC; Jain P; Tzankov A; Visco C; Bhagat G; Wang J; Dybkaer K; Tam W; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Møller MB; Winter JN; Piris MA; Fayad L; Liu Y; Song Y; Orlowski RZ; Kantarjian H; Medeiros LJ; Li Y; Cortes J; Young KH
Leukemia; 2018 Feb; 32(2):353-363. PubMed ID: 28745330
[TBL] [Abstract][Full Text] [Related]
30. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.
Carreras J; Yukie Kikuti Y; Miyaoka M; Hiraiwa S; Tomita S; Ikoma H; Kondo Y; Shiraiwa S; Ando K; Sato S; Suzuki Y; Miura I; Roncador G; Nakamura N
Am J Surg Pathol; 2018 Jul; 42(7):936-950. PubMed ID: 29738359
[TBL] [Abstract][Full Text] [Related]
31. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma.
Han B; Yim J; Lim S; Na S; Lee C; Kim TM; Paik JH; Kim S; Jeon YK
Mod Pathol; 2023 Sep; 36(9):100224. PubMed ID: 37257823
[TBL] [Abstract][Full Text] [Related]
33. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
34. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.
Chung R; Lai R; Wei P; Lee J; Hanson J; Belch AR; Turner AR; Reiman T
Blood; 2007 Aug; 110(4):1278-82. PubMed ID: 17475910
[TBL] [Abstract][Full Text] [Related]
35. High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma.
Chang C; Wu SY; Kang YW; Lin KP; Chen TY; Medeiros LJ; Chang KC
Am J Clin Pathol; 2015 Dec; 144(6):935-44. PubMed ID: 26573001
[TBL] [Abstract][Full Text] [Related]
36. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
37. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study.
Talaulikar D; Dahlstrom JE; Shadbolt B; McNiven M; Broomfield A; Pidcock M
Pathology; 2007 Dec; 39(6):580-5. PubMed ID: 18027262
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
Mitterbauer-Hohendanner G; Mannhalter C; Winkler K; Mitterbauer M; Skrabs C; Chott A; Simonitsch-Klupp I; Gleiss A; Lechner K; Jaeger U
Leukemia; 2004 Jun; 18(6):1102-7. PubMed ID: 15085149
[TBL] [Abstract][Full Text] [Related]
40. High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.
Song MK; Chung JS; Lee JJ; Yang DH; Kim IS; Shin DH; Shin HJ
Int J Hematol; 2015 Feb; 101(2):140-7. PubMed ID: 25504496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]